laromestrocel (Lomecel-B)

^[1]

Indications

mild Alzheimer's disease
- intravenous infusion ~1 minute duration without premedication
- 25 million cells*/infusion monthly, once or for 4 months
frailty dose 100 million cells single infusion

* difficult to assess any benefit in 100 million cells vs 25 million cells

made from mesenchymal stem cells isolated from fresh bone marrow cells donated by adults 18-45 years
pacrine activity
- may reduce inflammation, & stimulate nearby stem cells to promote regenerative & repair responses.
- may release exosomes, with cargo of RNA, proteins, & other molecules taken up by other cells with beneficial effects
- potential to form nanotube bridges, which can allow the exchange of mitochondria & other cellular contents between cells
improves 6 minute walk test distance
decreases soluble tyrosine protein kinase receptor TEK (degradation product)
- dosage dependent, TEK (CD202b, TIE2) is a human longevity protein

↑ Rash BG, Ramdas KN, Agafonova N et al Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial. Nat Med. 2025 Apr;31(4):1257-1266. . PMID: https://pubmed.ncbi.nlm.nih.gov/40065171 PMCID: PMC12003194 Free PMC article. Clinical Trial. https://pmc.ncbi.nlm.nih.gov/articles/PMC12003194/